SavedAdd your journal

Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2009 / Cilt: 19 - Sayı: 3

Lipoprotein (a) levels in patients with essential hypertension

Esansiyel hipertansiyonlu hastalarda lipoprotein (a) düzeyleri

Işıl ÇOKER
Ayfer ÇOLAK
Hakan TURKON
Ömür YILDIZ
Aybüke Günaslan HASTÜRK
İsmail KARADEMİRCİ
Pages
95–99
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: In the current study, there was no significant increase identified in the lipoprotein (a) levels of the isolated essential hypertension patients comparing with the control group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: The aim of this study is to measure the lipoprotein (a) levels in the esantial hypertension patients and to evaluate the correlation of essential hypertension and lipoprotein (a) levels.
📊
Key Findings & Data:MATERIAL AND METHOD: 128 patients submitted to the clinic of internal medicine in Tepecik Teaching and Research Hospital have been included in our study. 82 of them were diagnosed as essential hypertansion, 43 were females and 39 were males with an age range of 30-67. 46 individuals have been included in the control group, 26 were females and 20 were males with an age range of 30-59.
💡
Conclusion & Impact:CONCLUSION: In the current study, there was no significant increase identified in the lipoprotein (a) levels of the isolated essential hypertension patients comparing with the control group.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Risk faktörleri · Hipertansiyon · Lipoprotein(a)

Abstract

AIM: The aim of this study is to measure the lipoprotein (a) levels in the esantial hypertension patients and to evaluate the correlation of essential hypertension and lipoprotein (a) levels. MATERIAL AND METHOD: 128 patients submitted to the clinic of internal medicine in Tepecik Teaching and Research Hospital have been included in our study. 82 of them were diagnosed as essential hypertansion, 43 were females and 39 were males with an age range of 30-67. 46 individuals have been included in the control group, 26 were females and 20 were males with an age range of 30-59. Serum lipoprotein(a) levels have been measured with immunoturbidimetric method. Dialab (GmbH Austria) kits have been used in the Roche Modüler P 800 autoanalyzer for the evaluation. Total cholesterol, trigliceride, HDL levels have been measured with the enzymatic method. Roche Diagnostic kits have been utilized in the Roche Modüler P 800 autoanalyzer for the evaluation. All statistical tests were performed using the SPS 11.0 data analysis program. Data were analyzed using student t-test. FINDINGS: Lipoprotein (a) levels were found as 18.5 mg/dL in the patient with essential hypertension group, while 17.4 mg/dL in the control group (p=0.778). CONCLUSION: In the current study, there was no significant increase identified in the lipoprotein (a) levels of the isolated essential hypertension patients comparing with the control group.

Özet

AMAÇ: Bu çalışmanın amacı esansiyel hipertansiyonlu hastalarda lipoprotein (a) düzeylerini ölçerek, esansiyel hipertansiyon ile lipoprotein (a) düzeyleri arasında anlamlı bir ilişki olup olmadığını araştırmaktır. GEREÇ VE YÖNTEM: Çalışmamıza 2006-2007 yılları arasında Tepecik Eğitim Araştırma Hastanesi dahiliye polikliniğine başvuran 128 hasta alındı. Çalışma grubumuzu, bu olgulardan esansiyel hipertansiyon tanısı alan 82 (43K, 39E; 30-67 yaş arasında) kişi oluşturdu. Kontrol grubumuz ise 26'sı kadın ve 20'si erkek olmak üzere 46 kişi (30-59 yaş arasında) idi. Serum lipoprotein (a) düzeyleri, Roche Modüler P 800 otoanalizöründe Dialab marka (GmbH Austria) kitler kulanılarak immunotürbidimetrik yöntemle ölçüldü. Serum total kolesterol, trigliserid, HDL düzeyi ölçümleri Roche Modüler P 800 otoanalizöründe Roche Diagnostic kitleri kullanılarak enzimatik yöntem ile ölçüldü. Sonuçların değerlendirilmesinde bağımsız örnek student-t testi kullanıldı, SPSS 11.0 programı ile istatistiği yapıldı. BULGULAR: Esansiyel hipertansiyon grubunda lipoprotein (a) ortalaması 18.5 mg/dL, kontrol grubunda lipoprotein (a) ortalaması 17.4 mg/dL bulunmuştur (p=0.778 ). SONUÇ: Çalışmamızda, arter duvarlarında ateroskleroza eğilimi arttırdığı bilinen ve koroner kalp hastalıklarında risk faktörü olarak kabul edilen lipoprotein(a)'nın, izole hipertansiyon hastalarında kontrol grubuna göre anlamlı düzeyde yükselmediğini saptadık.

🔖

Cite This Article

ÇOKER, I., ÇOLAK, A., TURKON, H., YILDIZ, Ö., HASTÜRK, A. G., KARADEMİRCİ, İ. (2009). Lipoprotein (a) levels in patients with essential hypertension. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 19 - Sayı: 3, 95–99. https://ajindex.com/articles/268459

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bhavani BA, Padma T, Sastry B, Reddy NK. Plasma Lipoprotein (a) levels in patients with untreated essential hypertension. Indian J Hum Genet 2003; 9: 65-8
  2. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370:591-603
  3. Ballermann BJ, Dardik A, Eng E, Liu A. Shear stress and the endothelium. Kidney Int Suppl 1998; 67: S100-8
  4. Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity: impact on cardiovascular disease. Circulation 1998;98:1472-6
  5. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999; 131:376-86
  6. Luscher TF. Heterogeneity of endothelial dysfunction in hypertension. Eur Heart J 1992; 13 Suppl D: 50-5
  7. Catena C,Novello M,Lapenna R,Baroselli S,Colussi G,Nadalini E, et al.New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a).J.Hypertens 2005 Sep.23(9): 1617-31 8. Jelakovic B, Laganovic M, Kuzmanic D. [Lipoprotein(a)-a mysterious factor in atherogenesis]. Lijec Vjesn 2002; 124: 366-71
  8. Strong JP. Atherosclerotic lesions. Natural history, risk factors, and topography. Arch Pathol Lab Med 1992; 116: 1268-75
  9. Sen S, Yilmaz ME, Ustundag S, Azcan SN. Endothelial and vascular dysfunction in essential hypertension without target organ damage. Official J Turkish Soc Nephrol 2001; 10 (1): 57-62
  10. Massy ZA, Keane WF. Pathogenesis of atherosclerosis. Semin Nephrol. 1996; 16:12-20
  11. Weir MR, Maibach EW, Bakris GL, Black HR, Chawla P, Messerli FH, et al. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med. 2000; 160: 481-90
  12. Turner ST, Boerwinkle E. Genetics of hypertension, target- organ complications, and response to therapy. Circulation 2000; 102: IV40-5 14. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008 Sep 2; 118 (10): 993-1001
  13. Cobble M, Bale B. Carotid intima-media thickness: knowledge and application to everyday practice. Postgrad Med. 2010 Jan; 122(1): 10-8
  14. Kizer JR, Krauser DG, Rodeheffer RJ, Burnett JC Jr, Okin PM, Roman MJ, et al. Prognostic value of multiple biomarkers in American Indians free of clinically overt cardiovascular disease (from the Strong Heart Study). Am J Cardiol. 2009 Jul 15; 104 (2): 247-53 17. Reisin E, Messerli FH. Ob